EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of hyperkalaemia on renin–angiotensin–aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation

Hugh Logan Ellis, Mohammad Al-Agil, Philip A Kelly, James Teo, Claire Sharpe, Martin B Whyte

Clinical and Experimental Medicine · 21.12.2024 · 25 (1)

DOI: 10.1007/s10238-024-01531-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 21.12.2024. Verfasst von Hugh Logan Ellis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, King's College Hospital NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Hyperkalemia, Hospitalization, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhibitors of the renin–angiotensin–aldosterone system (RAAS), such as ACE inhibitors (ACEi), angiotensin-II receptor blockers and mineralocorticoid receptor antagonists, reduce morbidity and mortality in hypertension, congestive heart failure and chronic kidney disease. However, their use can lead to hyperkalaemia. We examined the proportions of RAAS inhibitor (RAASi) reduction or withdrawal, across GFR strata, following hospitalisation and the effect on patient mortality.

Methods

This was a retrospective cohort study of adult patients hospitalised from 1 January2017 to 31 December2020. Biochemistry data, clinical notes and medicines use were extracted using the CogStack platform, from electronic health records. Patients were identified by creatinine measurement during hospitalisation. Hyperkalaemia was defined as potassium > 5.0 mmol/L, with severity categorisation. RAASi discontinuation defined as ≥ 48 h without administration. Mortality risk associated with RAASi cessation was assessed using Cox proportional hazards models.

Results

Among 129,172 patients with potassium measurements, 49,011 were hospitalised. Hyperkalaemia prevalence was 8.57% in the emergency department and 16.79% among hospitalised patients. Higher hyperkalaemia levels correlated with increased CKD and heart failure. RAASi use was more common in hyperkalaemic patients, with higher discontinuation rates during hospitalisation (36% with potassium 5–5.5 mmol/L; 61% with potassium > 6.5 mmol/L). By discharge, 32% of patients had RAASi stopped, and 2% doses reduced. Discontinuation of RAASi was associated with 37% worse survival probability.

Conclusion

RAASi cessation was greater with hyperkalaemia and associated with increased mortality in hospitalised patients. Reinstitution of RAASi after hospital discharge, or alternative management of hyperkalaemia if maintained on RAASi therapy, may improve clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaHospitalizationAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedRenin-Angiotensin SystemAdultAged, 80 and overHeart FailureMineralocorticoid Receptor AntagonistsRenal Insufficiency, ChronicPotassiumHypertension

Stichwörter der Autor:innen

ACE inhibitorsHyperkalaemiaMortalityRenin–angiotensin system

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsMineralocorticoid Receptor AntagonistsPotassium

Autor:innen und Institutionen

  • Department of Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Department of Basic and Clinical Neuroscience, School of Neuroscience, King's College London, London, UK.
  • Department of Renal Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Education Centre, School of Medicine, University of Nottingham, Nottingham, UK.
  • Department of Medicine, King's College Hospital NHS Foundation Trust, London, UK. m.b.whyte@surrey.ac.uk.
  • Department Clinical and Exp Medicine, Faculty of Health and Medical Sciences, University of Surrey, Leggett Building, Daphne Jackson Road, Guildford, UK. m.b.whyte@surrey.ac.uk.

Förderung

  • AstraZeneca

Zitieren

APA

Ellis, H. L., Al-Agil, M., Kelly, P. A., Teo, J., Sharpe, C., & Whyte, M. B. (2024). Impact of hyperkalaemia on renin–angiotensin–aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation. Clinical and Experimental Medicine, 25(1). https://doi.org/10.1007/s10238-024-01531-9

Vancouver

Ellis HL, Al-Agil M, Kelly PA, Teo J, Sharpe C, Whyte MB. Impact of hyperkalaemia on renin–angiotensin–aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation. Clinical and Experimental Medicine. 2024;25(1). doi:10.1007/s10238-024-01531-9

BibTeX
@article{Ellis2024,
  author = {Ellis, Hugh Logan and Al-Agil, Mohammad and Kelly, Philip A and Teo, James and Sharpe, Claire and Whyte, Martin B},
  title = {Impact of hyperkalaemia on renin–angiotensin–aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  volume = {25},
  number = {1},
  doi = {10.1007/s10238-024-01531-9}
}
Kostenlos starten →